June 2023 ACIP Meeting - Dengue Vaccines

• 2023

  Sign in to bookmark this resource.

  Sign in

---

Access Resources

• LectureEN

About

In the ACIP meeting, experts reviewed dengue vaccination strategies using the Notre Dame and Takeda models. Dr. Wilbur Chen noted prior dengue infection doesn't fully protect against severe complications from different virus types; Dengvaxia was approved for children aged 9 to 16 in endemic areas. The workgroup evaluates TAK-003 from Takeda, considering policy and economic impacts, aiming for a recommendation by October 2023 pending licensure. Dr. Hernandez used the PICO framework for policy questions, emphasizing endemic area residents. Dr. Kaul presented economic models for Puerto Rico. Varied efficacy for Dengue 3 and 4 and the impact of pre-vaccination screening on cost-effectiveness were discussed, emphasizing age and serostatus in vaccination strategies.

---

Tags

Hazard: Infectious Disease

Audiences: Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Keywords: Dengue; Dengue Virus; Mosquito-Borne Diseases; Dengue Vaccines; Mosquito Vectors

Institutions: Centers for Disease Control and Prevention (CDC)

---

More like this

Hurricane Recovery 2018 · Centers for Disease Control and Prevention (CDC), Substance Abuse and Mental Health Services Administration (SAMHSA) Rural Emergency Preparedness and Response Toolkit None · Rural Health Information Hub One Health 2023 · Centers for Disease Control and Prevention (CDC)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---